Atara Biotherapeutics (ATRA) Cash & Current Investments (2013 - 2026)

Atara Biotherapeutics has reported Cash & Current Investments for 14 years, with the latest figure at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 39.31% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (down 39.31% YoY), and the FY2025 full-year result was $8.5 million, down 66.24% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $8.4 million, down from $8.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $265.4 million in Q3 2022, with the low at $8.4 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $65.8 million across 5 years, with a median of $46.0 million in 2023.
• The largest YoY upside for Cash & Current Investments was 134.04% in 2022 against a maximum downside of 80.71% in 2022.
• Atara Biotherapeutics' Cash & Current Investments stood at $242.8 million in 2022, then plunged by 78.7% to $51.7 million in 2023, then slumped by 51.33% to $25.2 million in 2024, then sank by 66.24% to $8.5 million in 2025, then retreated by 1.18% to $8.4 million in 2026.
• The last three Cash & Current Investments figures came in at $8.4 million (Q1 2026), $8.5 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.